Antimicrobial Resistance (AMR) is no longer a looming threat – it is today’s healthcare emergency, straining India’s hospitals, finances, and workforce. Drug-resistant infections are keeping patients in hospitals longer, driving up treatment costs, reducing bed availability, and pushing families into financial distress. In this authored article, Dr. Divya Joshi, Consultant–Infectious Diseases at Fortis Hospital, Bengaluru, argues that AMR is not just a clinical issue but a systemic crisis that demands urgent, coordinated action from hospitals, policymakers, and communities alike.
Antimicrobial resistance (AMR) is no longer a distant threat, it is a full-blown crisis strangling India’s healthcare system. Fueled by widespread misuse of antibiotics in hospitals, unregulated pharmacies and livestock farming, AMR is breeding superbugs that defy treatment, leading to skyrocketing costs, prolonged hospital stays, higher mortality, and a weakened workforce. Having spent decades navigating India’s healthcare challenges, I see AMR as a self-inflicted wound – a major failure of oversight and accountability that now threatens our economic and social fabric.
The implications are staggering. Hospitals are under pressure as multidrug-resistant infections disrupt clinical protocols and stretch budgets. Patients and their families face greater financial strain. Productivity is lost when working-age individuals spend more time recovering or in the worst cases, do not recover at all. AMR is no longer just a medical problem, it can cause 1.2 million AMR associated deaths by 2030 if no action is taken. It is a ‘Systems Problem’ – one that calls for urgent action from hospital administrators, policymakers and healthcare leaders who have the power to change its trajectory.
The Hidden Cost Hospitals Are Already Paying
For hospitals, AMR is more than a clinical challenge, it is an economic one. Multidrug-resistant infections translate into longer patient stays, higher use of expensive last-line drugs, and a surge in critical care needs. Each prolonged hospitalization not only increases the cost per patient but also reduces bed availability for new admissions, disrupting patient flow and revenue cycles. Operationally, AMR drives up diagnostic workloads, increases pressure on infection control teams and complicates resource planning.
This is no small drain on India’s healthcare budget. Studies have shown that treating drug-resistant infections can cost up to four times more than treating drug-sensitive cases. For hospitals that already operate on thin margins, these costs are unsustainable.
The Economic, Operational and Human Fallout
Antimicrobial resistance is slowly reshaping how India’s healthcare system works and the consequences are hitting hospitals hard. When infections refuse to respond to routine drugs patients stay admitted far longer than expected. Beds remain occupied for weeks, and wards start to overflow. Doctors are forced to use stronger, more expensive medicines and when infections come back, the cycle repeats. For hospital teams already under pressure, it feels like fighting a battle that keeps moving the goalposts. The extra costs pile up, straining budgets and leaving administrators to juggle between care quality and financial survival.
But the problem does not start or end within hospital walls. Antibiotics continue to be sold without prescriptions in countless pharmacies and farms still use them freely to boost livestock growth. This misuse seeps into food chains and water systems and spreads resistant bacteria everywhere. What reaches hospitals is only the visible tip of a much larger problem. Treating AMR as a purely clinical issue surely is no longer enough. It is draining resources, disrupting operations and threatening the way care is delivered.
The human toll is even harder to absorb. Each year, drug-resistant infections take the lives of thousands of newborns in India. For many others, recovery is painfully slow, with complications, organ damage and repeated hospital visits. Families often burn through their savings or take loans to pay for treatment and for some, the financial hit is enough to push them below the poverty line.
The impact on the workforce is just as severe. Resistant infections keep labourers away from construction sites, farmers from tending fields, and professionals from offices. Each missed day of work chips away at productivity and weakens household incomes. Over time, this health crisis becomes an economic one, slowing India’s growth engine. The ripple effect does not stop at hospital doors, it stretches into communities, affects businesses and quietly shapes the nation’s future.
Small Wins, Big Potential
India has tools to fight back. The National Action Plan on AMR (NAP-AMR), which started in 2017, focuses on keeping watch using antibiotics, and stopping infections. Hospitals that use Antimicrobial Stewardship Programs (AMS) have cut down wrong antibiotic prescriptions by up to 70% saving drugs and slowing down resistance. Big city hospitals that use pharmacist-led checks and quick tests have made treatments shorter, freeing up resources. These wins show what’s possible, but they’re still small in scale. Scaling them requires relentless commitment.
The Way Forward
We need a clear, coordinated strategy. Hospitals must integrate antimicrobial stewardship into their core operations, not as a compliance checklist but as a business imperative. Policymakers must incentivize responsible antibiotic use, fund AMR research and make diagnostics more accessible so that doctors can prescribe with precision. Awareness campaigns targeting both healthcare workers and the public are crucial to shift behavior.
Kerala’s experience offers a strong model of what works. In 2018, the state launched the Kerala Antimicrobial Resistance Strategic Action Plan (KARSAP), aligned with national and WHO action plans. Its strength lay in a multi-sectoral approach that brought together healthcare professionals, veterinarians, pharmacists, and policymakers. Kerala built one of India’s first state-level AMR surveillance networks, integrating medical college and district hospital labs for real-time data on resistant pathogens. This data drove antibiotic stewardship, while infection prevention programs, focused on hand hygiene, biomedical waste management, and rational antibiotic use, strengthened hospital practices. Public campaigns on responsible antibiotic use, tighter controls on over-the-counter sales, and strong community engagement completed the loop. Kerala’s journey shows that with political will, evidence-based strategy, and community participation, AMR can be tackled systematically. It is proof that state-led initiatives can become blueprints for national action.
Most importantly, we must stop viewing AMR as a future threat and start treating it as today’s crisis. Tackling AMR now is not just a public health responsibility, it is an economic necessity. The longer we wait, the higher the price we will all pay.
